公开(公告)号：EP3904332A1

公开(公告)日：2021-11-03

申请号：EP21177619.0

申请日：2012-10-15

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services ,  The Cooper Health System ,  SRI International

发明人： WAINER, Irving, W. ,  MOADDEL, Ruin ,  BERNIER, Michel ,  ZARATE, Carlos, A. ,  TORJMAN, Marc, C. ,  GOLDBERG, Michael, E. ,  TANGA, Mary, J.

IPC分类号： C07C225/20 ,  A61K31/135 ,  A61P21/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00

摘要： The disclosure provides a pharmaceutical composition comprising a compound of the Formula

or

or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient, wherein the composition is formulated for oral administration to a human and contains 0.2 mg to 500 mg of the compound or a salt thereof.

公开(公告)号：EP2766339A1

公开(公告)日：2014-08-20

申请号：EP12783752.4

申请日：2012-10-15

申请人： The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ,  The Cooper Health System

发明人： WAINER, Irving, W. ,  MOADDEL, Ruin ,  BERNIER, Michel ,  ZARATE, Carlos, A. ,  TORJMAN, Marc, C. ,  GOLDBERG, Michael, E. ,  TANGA, Mary, J.

IPC分类号： C07C225/20 ,  C07C237/02 ,  C07D295/155 ,  C07D295/145 ,  A61P25/04 ,  A61P25/28 ,  A61P25/00 ,  A61K31/133 ,  A61K31/122

CPC分类号： A61K31/5375 ,  A61K31/137 ,  A61K31/165 ,  A61K31/222 ,  A61K31/24 ,  A61K31/265 ,  A61K31/4453 ,  C07B2200/07 ,  C07C225/20 ,  C07C229/48 ,  C07C237/04 ,  C07C237/20 ,  C07C2601/14 ,  C07C2601/16 ,  C07D295/108 ,  C07D295/112 ,  C07D295/15 ,  C07D295/155

摘要： The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.

摘要翻译： 因此，本发明提供了新颖的氯胺酮代谢物的前体药物。 本公开提供治疗双相抑郁症，重度抑郁症，神经性疼痛和慢性疼痛，包括复杂区域疼痛合成疼痛障碍（CRPD）通过给予纯化氯胺酮的代谢产物或代谢氯胺酮前体药物直接有需要的患者寻求治疗的方法。